Article
Efficacy and safety of glecaprevir and pibrentasvir in Japanese patients with hepatitis C virus infection aged 75 years or older.
BMC gastroenterology - 28 Apr 2022
Komaki Yuri, Ozono Yoshinori, Nakamura Kenichi, Iwakiri Hisayoshi, Hasuike Satoru, Sueta Mitsue, Miike Tadashi, Yamamoto Shojiro, Uto Hirofumi, Kusumoto Kazunori, Ochiai Toshimasa, Kato Junya, Komada Naoto, Kuroki Kazuo, Eto Toshiharu, Shigehira Masafumi, Hirono Shuichi, Nagata Kenji, Kawakami Hiroshi
Abstract excerpt
BACKGROUND: It is estimated that approximately 50% of patients with hepatitis C virus (HCV) infection in Japan are currently over 75 years old. However, patients aged ≥ 75 years are typically underrepresented in clinical trials of direct-acting antivirals. This study aimed to evaluate the efficacy and safety of glecaprevir and pibrentasvir (G/P) treatment in Japanese patients with HCV infection aged ≥ 75 years....
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.